GLUCAGON RECEPTOR MODULATOR

or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, A1, A2, A3, A4, L, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions th...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	PFEFFERKORN Jeffrey Allen, DIDIUK Mary Theresa, FILIPSKI Kevin James, ASPNES Gary Erik, TU Meihua Mike, GUZMAN-PEREZ Angel, LEE Esther Cheng Yin, STEVENS Benjamin Dawson
Format:	Patent
Sprache:	eng ; slv
Schlagworte:	CHEMISTRY HETEROCYCLIC COMPOUNDS METALLURGY ORGANIC CHEMISTRY
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page
container_issue
container_start_page
container_title
container_volume
creator	PFEFFERKORN Jeffrey Allen DIDIUK Mary Theresa FILIPSKI Kevin James ASPNES Gary Erik TU Meihua Mike GUZMAN-PEREZ Angel LEE Esther Cheng Yin STEVENS Benjamin Dawson
description	or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, A1, A2, A3, A4, L, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.
format	Patent
fullrecord	<record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_SI2673260TT1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>SI2673260TT1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_SI2673260TT13</originalsourceid><addsrcrecordid>eNrjZJB29wl1dnT391MIcnV2DQjxD1Lw9XcJ9XEEsngYWNMSc4pTeaE0N4Oim2uIs4duakF-fGpxQWJyal5qSXywp5GZubGRmUFIiKExMWoAbDwhJw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>GLUCAGON RECEPTOR MODULATOR</title><source>esp@cenet</source><creator>PFEFFERKORN Jeffrey Allen ; DIDIUK Mary Theresa ; FILIPSKI Kevin James ; ASPNES Gary Erik ; TU Meihua Mike ; GUZMAN-PEREZ Angel ; LEE Esther Cheng Yin ; STEVENS Benjamin Dawson</creator><creatorcontrib>PFEFFERKORN Jeffrey Allen ; DIDIUK Mary Theresa ; FILIPSKI Kevin James ; ASPNES Gary Erik ; TU Meihua Mike ; GUZMAN-PEREZ Angel ; LEE Esther Cheng Yin ; STEVENS Benjamin Dawson</creatorcontrib><description>or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, A1, A2, A3, A4, L, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.</description><language>eng ; slv</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; METALLURGY ; ORGANIC CHEMISTRY</subject><creationdate>2016</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20161028&DB=EPODOC&CC=SI&NR=2673260T1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76290</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20161028&DB=EPODOC&CC=SI&NR=2673260T1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>PFEFFERKORN Jeffrey Allen</creatorcontrib><creatorcontrib>DIDIUK Mary Theresa</creatorcontrib><creatorcontrib>FILIPSKI Kevin James</creatorcontrib><creatorcontrib>ASPNES Gary Erik</creatorcontrib><creatorcontrib>TU Meihua Mike</creatorcontrib><creatorcontrib>GUZMAN-PEREZ Angel</creatorcontrib><creatorcontrib>LEE Esther Cheng Yin</creatorcontrib><creatorcontrib>STEVENS Benjamin Dawson</creatorcontrib><title>GLUCAGON RECEPTOR MODULATOR</title><description>or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, A1, A2, A3, A4, L, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2016</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZJB29wl1dnT391MIcnV2DQjxD1Lw9XcJ9XEEsngYWNMSc4pTeaE0N4Oim2uIs4duakF-fGpxQWJyal5qSXywp5GZubGRmUFIiKExMWoAbDwhJw</recordid><startdate>20161028</startdate><enddate>20161028</enddate><creator>PFEFFERKORN Jeffrey Allen</creator><creator>DIDIUK Mary Theresa</creator><creator>FILIPSKI Kevin James</creator><creator>ASPNES Gary Erik</creator><creator>TU Meihua Mike</creator><creator>GUZMAN-PEREZ Angel</creator><creator>LEE Esther Cheng Yin</creator><creator>STEVENS Benjamin Dawson</creator><scope>EVB</scope></search><sort><creationdate>20161028</creationdate><title>GLUCAGON RECEPTOR MODULATOR</title><author>PFEFFERKORN Jeffrey Allen ; DIDIUK Mary Theresa ; FILIPSKI Kevin James ; ASPNES Gary Erik ; TU Meihua Mike ; GUZMAN-PEREZ Angel ; LEE Esther Cheng Yin ; STEVENS Benjamin Dawson</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_SI2673260TT13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; slv</language><creationdate>2016</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><toplevel>online_resources</toplevel><creatorcontrib>PFEFFERKORN Jeffrey Allen</creatorcontrib><creatorcontrib>DIDIUK Mary Theresa</creatorcontrib><creatorcontrib>FILIPSKI Kevin James</creatorcontrib><creatorcontrib>ASPNES Gary Erik</creatorcontrib><creatorcontrib>TU Meihua Mike</creatorcontrib><creatorcontrib>GUZMAN-PEREZ Angel</creatorcontrib><creatorcontrib>LEE Esther Cheng Yin</creatorcontrib><creatorcontrib>STEVENS Benjamin Dawson</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>PFEFFERKORN Jeffrey Allen</au><au>DIDIUK Mary Theresa</au><au>FILIPSKI Kevin James</au><au>ASPNES Gary Erik</au><au>TU Meihua Mike</au><au>GUZMAN-PEREZ Angel</au><au>LEE Esther Cheng Yin</au><au>STEVENS Benjamin Dawson</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>GLUCAGON RECEPTOR MODULATOR</title><date>2016-10-28</date><risdate>2016</risdate><abstract>or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, A1, A2, A3, A4, L, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.</abstract><oa>free_for_read</oa></addata></record>
fulltext	fulltext_linktorsrc
identifier
ispartof
issn
language	eng ; slv
recordid	cdi_epo_espacenet_SI2673260TT1
source	esp@cenet
subjects	CHEMISTRY HETEROCYCLIC COMPOUNDS METALLURGY ORGANIC CHEMISTRY
title	GLUCAGON RECEPTOR MODULATOR
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T15%3A50%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=PFEFFERKORN%20Jeffrey%20Allen&rft.date=2016-10-28&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ESI2673260TT1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true